ESTRO 2023 - Abstract Book

S2003

Digital Posters

ESTRO 2023

and MES subtypes have been shown to be more radioresistant than the PN subtype. If confirmed in patients, the molecular subtype could predict the specific benefit of radiotherapy. The aim of this work is therefore to investigate whether GB molecular subtypes are associated with radiation resistance in vivo. Materials and Methods We analysed the spatiotemporal pattern of recurrence (locoregional relapse and in-field relapse) in 55 GB patients treated with adjuvant radiotherapy (30 x 2 Gy, following EORTC contouring guidelines) using the Stupp’s regime included in a prospective multicentric study (GLIOCAT). We defined relapse following the RANO criteria and classified it spatially in 3 groups: in-field relapse (Dmin > 57 Gy), out-of-field relapse (Dmax < 30 Gy) and undefined (marginal relapse or no follow- up MR data). We used the Support Vector Machine (SVM) model for the transcriptomic classification of tumour samples. Patients with an undefined spatial pattern of recurrence were included in the progression-free survival (PFS) analysis but excluded from the in-field relapse analysis. Results The transcriptomic classification resulted in 26 CL, 12 MES and 17 PN. These groups were balanced with respect to the surgical procedure. Median PFS after radiotherapy was 4 months, with a median follow-up of 12 months. No differences in PFS were found between the different molecular subtypes (see figure 1a). However, we found differences in the in-field relapse-free survival between molecular subtypes, with a median time-to-event of 2.1 months (CL), 6.3 months (MES) and 6.9 months (PL) (figure 1b). These differences are statistically non-significant, probably due to reduced number of patients in each group (10 CL, 7 MES and 8 PL).

Figure 1: (a) Relapse-free survival probability and (b) in-field relapse-free survival probability, as a function of time (in months) for the different GB molecular subtypes: Classical, Mesenchymal and Proneural. Conclusion Although there is no difference in PFS among GB molecular subtypes, the results of this work seem to suggest that the Classical subtype relapses faster inside the radiotherapy field than the other subtypes. These findings would imply a higher radioresistance of the Classical subtype. Although these differences are statistically non-significant, they provide the rationale for further investigation in a larger patient cohort.

PO-2227 Uncovering Proton Boron Capture Therapy: In-vitro Cell Irradiation and Monte Carlo Simulations

V.L. Jacobsen 1,4 , J.G. Johansen 1 , B.S. Sørensen 2 , H.O.U. Fynbo 3 , M. Sitarz 1 , A.T. Frederiksen 2 , N. Bassler 1,4

1 Aarhus University Hospital, Danish Centre for Particle Therapy, Aarhus, Denmark; 2 Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus, Denmark; 3 Aarhus University, Department of Physics and Astronomy, Aarhus, Denmark; 4 Aarhus University, Department of Clinical Medicine, Aarhus, Denmark Purpose or Objective In 2018, an enhanced relative biological effect (RBE) was reported when DU-145 prostate cancer cells had been exposed to sodium borocaptate (BSH) prior to irradiation with protons [1]. The increased RBE was hypothesised to stem from the three- alpha decay resulting from p+11B reaction. However, Monte Carlo simulation studies predict only very few additional alpha- particles stemming from the 11B reaction, which led to the hypothesis that other unknown mechanisms may be at work. In